Tonix Pharmaceuticals Holding has been granted a patent for a method to treat major depressive disorder in fibromyalgia patients using a pharmaceutical composition containing cyclobenzaprine. The treatment aims to ameliorate or eliminate depression with a low daily dosage of less than 5 mg. GlobalData’s report on Tonix Pharmaceuticals Holding gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Tonix Pharmaceuticals Holding, Cancer treatment biomarkers was a key innovation area identified from patents. Tonix Pharmaceuticals Holding's grant share as of May 2024 was 34%. Grant share is based on the ratio of number of grants to total number of patents.
A recently granted patent (Publication Number: US11998516B2) discloses a method for treating major depressive disorder in fibromyalgia patients. The method involves administering a pharmaceutical composition containing cyclobenzaprine or its salt, along with a carrier. The treatment aims to ameliorate or eliminate the major depressive disorder, with the administered amount of cyclobenzaprine being less than 5 mg/day, and in some cases, less than 2.5 mg/day. Additionally, the method allows for the concurrent or sequential administration of the pharmaceutical composition with an antidepressant drug, and can be delivered in orally dissolving tablet or thin film formulation.
Furthermore, the patent claims suggest that the pharmaceutical composition can be combined with psychotherapeutic intervention for enhanced efficacy and is recommended to be administered at bedtime. This method offers a novel approach to addressing major depressive disorder in fibromyalgia patients, potentially providing a more targeted and effective treatment option. The patent's specific dosage and administration guidelines aim to optimize the therapeutic benefits of cyclobenzaprine while minimizing potential side effects, highlighting the importance of personalized and comprehensive care for individuals with this comorbid condition.
To know more about GlobalData’s detailed insights on Tonix Pharmaceuticals Holding, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
